Author | Year | Country | Study type | Number of TJA | Group | Age (years) | Gender F/M | BMI | Diagnosis | Type of TJA | Follow-Up | NOS |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Stambough et al. | 2017 | USA | Retrospective | 4186 | Screening | THA 58.2 ± 13.5 TKA 63.1 ± 9.6 | 1146/903 | THA 29.0 ± 5.0 TKA 32.1 ± 5.8 | NM | 1003TKA/1202THA | 90 days | 8 |
Control | THA 57.2 ± 14.1 TKA 63.3 ± 10.0 | 1031/833 | THA 29.3 ± 5.9 TKA 32.9 ± 6.4 | NM | 836TKA/1145THA | |||||||
Hofmann et al. | 2017 | USA | Retrospective | 1034 | Screening | 61.5 ± 11.6 | 324/214 | NM | degenerative joint disease | 306TKA/232 THA | ≥ 1 year | 8 |
Control | 60.6 ± 12.3 | 279/217 | NM | 294TKA/202THA | ||||||||
Hadley et al. | 2010 | USA | Retrospective | 2058 | Screening | NM | NM | NM | NM | TKA THA | 1 year | 7 |
Control | NM | NM | NM | NM | ||||||||
Sankar et al. | 2005 | UK | Prospective | 395 | Screening | 68.53 (48–77) | 141/90 | NM | OA: 381, RA: 12, AS: 2 | 106TKA/125THA | NM | 7 |
Control | 67.39 (51–79) | 106/58 | NM | 79TKA/85THA | ||||||||
Jeans et al. | 2018 | UK | retrospective | 12911 | Screening | 68.6 (16–99) | 5125/4193 | 29.9 (15.6–61) | NM | TKA THA | NM | 6 |
Control | 68.5 (22–100) | 1940/1653 | 29.5 (17.3–50.2) | NM | ||||||||
Rao et al. | 2011 | USA | Prospective | 2026 | Screening | NM | NM | NM | NM | TKA THA | 2 years | 6 |
Control | NM | NM | NM | NM | ||||||||
Hacek et al. | 2008 | USA | Retrospective | 1495 | Screening | 69.0 | 565/347 | NM | NM | (709TKA/786THA) | 1 year | 8 |
Control | 69.1 | 356/227 | NM | NM | ||||||||
Pelfort et al. | 2019 | Spain | Retrospective | 803 | Screening | 72.4 ± 6.9 | 278/125 | NM | NM | TKA | 1 year | 8 |
Control | 72.2 ± 6.8 | 266/134 | NM | NM | ||||||||
Sporer et al. | 2016 | UKA | Retrospective | 11133 | Screening | NM | 5819/3972 | NM | NM | 6175TKA/3661THA | 30 days | 7 |
Control | NM | 847/593 | NM | NM | 924TKA/ 516THA |